. 2021 Jun 17;38(7):4100–4114. doi: 10.1007/s12325-021-01786-8

Table 1.

Crude and adjusted prevalence and incidence of fibrosing ILD and progressive fibrosing ILD using a sensitive definition (requiring a single eligible claim) or a more specific definition requiring two claims

	Prevalence, per 100,000 persons (95% CI)	Incidence, per 100,000 PY (95% CI)
Fibrosing ILD
Sensitive: one claim	393.12 (391.12, 395.12)	453.88 (451.46, 456.29)	240.60 (239.28, 241.92)	273.15 (271.61, 274.69)
Specific: two claims	95.37 (94.38, 96.35)	117.82 (116.56, 119.08)	44.14 (43.57, 44.70)	51.56 (50.88, 52.24)
Progressive fibrosing ILD
Sensitive: one claim	158.60 (157.33, 159.87)	190.94 (189.34, 192.54)	92.47 (91.65, 93.28)	108.17 (107.19, 109.16)
Specific: two claims	57.82 (57.05, 58.58)	70.30 (69.32, 71.27)	27.55 (27.11, 28.00)	32.55 (32.01, 33.09)

Prevalence, per 100,000 persons
(95% CI)

Incidence, per 100,000 PY
(95% CI)

Crude

Adjusted*

Crude

Adjusted*

Fibrosing ILD

Sensitive: one claim

393.12

(391.12, 395.12)

453.88

(451.46, 456.29)

240.60

(239.28, 241.92)

273.15

(271.61, 274.69)

Specific: two claims

95.37

(94.38, 96.35)

117.82

(116.56, 119.08)

44.14

(43.57, 44.70)

51.56

(50.88, 52.24)

Progressive fibrosing ILD

Sensitive: one claim

158.60

(157.33, 159.87)

190.94

(189.34, 192.54)

92.47

(91.65, 93.28)

108.17

(107.19, 109.16)

Specific: two claims

57.82

(57.05, 58.58)

70.30

(69.32, 71.27)

27.55

(27.11, 28.00)

32.55

(32.01, 33.09)

CI confidence interval, ILD interstitial lung disease, PY patient-years

*Adjusted for age and sex